Astellas Targets Generic Versions Of Bladder Drug Myrbetriq

By Dani Kass (October 13, 2016, 4:04 PM EDT) -- Astellas Pharma Inc. on Thursday filed three lawsuits in Delaware federal court seeking to block generic versions of its patent-protected overactive bladder treatment Myrbetriq, which were proposed by Aurobindo Pharma, Windlas Healthcare, Prinston Pharmaceutical Inc., Huahai US Inc. and Solco Healthcare US....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!